GlassScriptPhysician profile
Tonya M May
NPI 1114287976
$6,940.34
in general payments reported to CMS, 2019-2025
34 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $950 · 2022: $1,291 · 2023: $1,211 · 2024: $1,499 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,618 · Education: $81.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,617.70 |
| Education | $81.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,804.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,138.48 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $766.34 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.09 | 2021-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $296.76 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $286.63 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $241.67 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $224.88 | 2021-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $210.72 | 2021-2023 | |
| Lilly USA, LLC | $198.06 | 2023-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $184.12 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $149.15 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $120.01 | 2024-2025 | Ibsrela |
| Pfizer INC. | $113.22 | 2021-2025 | |
| Boston Scientific Corporation | $110.40 | 2023-2024 | Watchman Access System, Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $100.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $92.45 | 2023-2024 | Gimoti |
| Genzyme Corporation | $71.05 | 2022-2023 | |
| Urogen Pharma, INC. | $41.97 | 2025 | |
| Endo USA, INC. | $38.66 | 2025 | Xiaflex |
| Urovant Sciences INC | $37.11 | 2022 | |
| Leica Microsystems INC. | $27.02 | 2025 | Neoprobe |
| Procept Biorobotics Corporation | $24.42 | 2023 | Aquabeam Robotic System |
| Allergan, INC. | $22.74 | 2022 | |
| Ambu INC. | $22.54 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.84 | 2025 | Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $18.45 | 2024 | Andexxa |
| Medtronic, INC. | $18.00 | 2021 | |
| Baxter Healthcare | $17.66 | 2025 | Perclot |
| Redhill Biopharma INC. | $16.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.95 | 2023 | |
| Solventum Corporation | $14.56 | 2025 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Vivus LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.